ArticleThe journal of international advanced otology2025
Efficacy of Low-Dose BoNT-A Acupoint Injections in Managing Headache, Vertigo, and Allodynia in Vestibular Migraine.
Article in The journal of international advanced otology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examines low-dose botulinum toxin at acupuncture points for its effects on vestibular symptoms, headaches, depression, anxiety, and stress in vestibular migraine patients.
methodsThis prospective study included patients with vestibular migraine per Barany Society criteria. Fifty units of Onabotulinum toxin were injected using a 31-gauge needle at 5 units/0.1 mL, diluted from 100 units with 2 mL of 0.9% sodium chloride. The injections were given at predetermined acupuncture points: Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20), and Tianzhu (BL10). Six-month follow-up assessments included assessments using the Migraine Disability Assessment Scale (MIDAS), Dizziness Handicap Inventory-Screening Form (DHI-S), Vertigo Symptom Scale-Short Form (VSS-SF), Depression Anxiety Stress Scale (DASS-21), and Allodynia Symptom Checklist (ASC-12).
resultsStatistically significant improvements were observed in MIDAS, VSS-SF, DHI-S, and DASS-21 scores at both 3 and 6 months (P < .05).
conclusionApplication of Onabotulinum toxin A (BoNT-A) to acupuncture points alleviated headache, vestibular symptoms, and anxiety, with benefits persisting for up to 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.